These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 37439782)

  • 21. Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant.
    Koster A; Loebe M; Mertzlufft F; Kuppe H; Hetzer R
    Ann Thorac Surg; 2000 Dec; 70(6):2160-1. PubMed ID: 11156147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Acute profound thrombocytopenia associated with tirofiban: clinical approach to diagnosis and therapeutic management].
    Agnelli D; Ottani F
    G Ital Cardiol (Rome); 2008 Feb; 9(2):137-43. PubMed ID: 18383777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events.
    Dunkley S; Evans S; Gaudry L; Jepson N
    Platelets; 2005 Dec; 16(8):462-8. PubMed ID: 16287613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions.
    Starnes HB; Patel AA; Stouffer GA
    Drugs; 2011 Oct; 71(15):2009-30. PubMed ID: 21985168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome.
    Mansur Ade P; Roggerio A; Takada JY; Caribé PM; Avakian SD; Strunz CM
    Sao Paulo Med J; 2016 Jan; 134(3):199-204. PubMed ID: 26786608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment.
    Mulot A; Moulin F; Fohlen-Walter A; Angioi M; Sghaier M; Carteaux JP; Lecompte T; de Maistre E
    Am J Hematol; 2004 Sep; 77(1):67-71. PubMed ID: 15307109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials.
    McKay RG; Boden WE
    Curr Opin Cardiol; 2001 Nov; 16(6):364-9. PubMed ID: 11704707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.
    Tcheng JE
    Am Heart J; 2000 Feb; 139(2 Pt 2):S38-45. PubMed ID: 10650315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
    Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML
    Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban.
    Koster A; Kukucka M; Bach F; Meyer O; Fischer T; Mertzlufft F; Loebe M; Hetzer R; Kuppe H
    Anesthesiology; 2001 Feb; 94(2):245-51. PubMed ID: 11176088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.
    Alexander KP; Chen AY; Newby LK; Schwartz JB; Redberg RF; Hochman JS; Roe MT; Gibler WB; Ohman EM; Peterson ED;
    Circulation; 2006 Sep; 114(13):1380-7. PubMed ID: 16982940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
    Stone GW; Moliterno DJ; Bertrand M; Neumann FJ; Herrmann HC; Powers ER; Grines CL; Moses JW; Cohen DJ; Cohen EA; Cohen M; Wolski K; DiBattiste PM; Topol EJ
    Circulation; 2002 May; 105(20):2347-54. PubMed ID: 12021219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Severe thrombocytopenia induced by tirofiban after percutaneous coronary intervention: a case report.
    Wang ZM; Wang B; Li YF; Chen B; Shen Q; Li DF; Wang LS
    J Med Case Rep; 2023 Oct; 17(1):430. PubMed ID: 37838704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention.
    Deshpande NV; Pratiti R; Admane P; Mukherjee D; Mardikar HM
    Indian Heart J; 2012; 64(5):444-8. PubMed ID: 23102380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tirofiban-associated acute thrombocytopenia.
    Tuhta AG; Yeşildağ O; Köprülü D
    Acta Cardiol; 2006 Oct; 61(5):577-9. PubMed ID: 17117761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Long-lasting thrombocytopenia induced by glycoprotein IIb/IIIa inhibitor].
    Christen JR; Soubrier C; Martinez E; Roumieu V; Darmon O; Scandaliaris S; Picou L; Cuisset T; Grados A; Bernit E; Ebbo M; Harlé JR; Schleinitz N
    Rev Med Interne; 2017 Nov; 38(11):769-773. PubMed ID: 28690092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use.
    Pang JT; Fort S; Della Siega A; Cohen EA
    J Card Surg; 2002; 17(5):425-31. PubMed ID: 12630543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.